NON HODGKIN LYMPHOMA (NHL)
Clinical trials for NON HODGKIN LYMPHOMA (NHL) explained in plain language.
Never miss a new study
Get alerted when new NON HODGKIN LYMPHOMA (NHL) trials appear
Sign up with your email to follow new studies for NON HODGKIN LYMPHOMA (NHL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR-T therapy tested for patients with aggressive blood cancers
Disease control Recruiting nowThis is an early safety study testing a new CAR-T cell therapy called LV009 for adults with certain blood cancers (like non-Hodgkin lymphoma or acute lymphoblastic leukemia) that have come back or not responded to other treatments. The main goals are to find a safe dose and see h…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
Two-Pronged attack: new cell therapy aims to outsmart resistant blood cancers
Disease control Recruiting nowThis study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Dual-Target attack: early trial tests new weapon against tough blood cancers
Disease control Recruiting nowThis early-phase study is testing the safety and initial effectiveness of a new cell therapy called OriV508 for adults with multiple myeloma or non-Hodgkin lymphoma that has returned or not responded to prior treatments. The therapy involves modifying a patient's own immune cells…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope drug enters human testing for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called NB02 (posseltinib) in patients with non-Hodgkin's lymphoma that has returned or stopped responding to standard treatments. The main goal is to find the safest dose and understand how the drug behaves in the body. Researchers wil…
Matched conditions: NON HODGKIN LYMPHOMA (NHL)
Phase: PHASE1 • Sponsor: NOBO Medicine • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC